Kymab
Meditrina (B260)
Babraham Research Campus
Cambridge
United Kingdom
CB22 3AT
United States
Tel: 44-0-1223-833301
Fax: 44-0-1223-839133
Website: http://www.kymab.com/
Email: media@kymab.com
32 articles about Kymab
-
The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
-
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
12/6/2019
Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based therapeutics, today announced that abstracts describing two lead hematology programs, KY1049 and KY1066, will be presented at the American Society of Hematology 61st Annual Meeting and Exposition, being held December 7-10, 2019 in Orlando, Florida.
-
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting
9/27/2019
Phase 1/2, open-label, multicenter study ongoing to evaluate KY1044 as a single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with advanced malignancies Cambr
-
Kymab And Seattle Children's Research Institute Publish Impressive Results Using Kymab’s KY1005 In A Model Of Acute Graft Versus Host Disease (Agvhd) In Science Translational Medicine
9/22/2017
-
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases
8/1/2017
-
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases
7/31/2017
-
Kymab Appoints Dr Sonia Quaratino As Chief Medical Officer
5/9/2017
-
Kymab Release: Biopharma Appoints Dr Arndt Schottelius As Executive Vice President Research & Development
1/23/2017
-
Kymab Expands Infectious Disease Programmes
1/9/2017
-
Kymab New Therapeutic Antibody For Autoimmune Diseases Shows Potential For Improvement In Post-Transplant Survival
12/5/2016
-
UK Antibodies Powerhouse Kymab Bags $100 Million and Two New Backers From China
11/28/2016
-
Shenzhen Hepalink Pharmaceutical Co., Ltd Invests $36.5 Million In Kymab's C Round
11/28/2016
-
ORI Teams Up With World Class Investors To Close The Series C Financing In Kymab
11/28/2016
-
Kymab And EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement
10/11/2016
-
Kymouse, Kymab's Human Antibody Discovery Platform, Successfully Demonstrates Steps To Developing HIV Vaccine
9/9/2016
-
Kymab And Heptares Enter Strategic Collaboration To Discover, Develop And Commercialise Novel Antibody Therapeutics
4/18/2016
-
Kymab Appoints Dr David Chiswell As Chief Executive Officer
3/17/2016
-
Kymab Succeeds In Revoking Regeneron’s UK VelocImmune Patents
2/2/2016
-
Kymab And MD Anderson Cancer Center Announce Strategic Partnership In Immuno-Oncology Research & Development
1/7/2016
-
Kymab Implements Genedata Biologics For High-throughput Antibody Discovery
11/17/2015